发布求助
文献互助 智能选刊 最新文献

Leukemia & Lymphoma最新文献

筛选
英文 中文
Double hit lymphoma masqueraded as clusters of crater-like nonhealing infectious skin lesions. 双重打击淋巴瘤伪装成群集的坑样不愈合感染性皮肤病变。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-05-09 DOI: 10.1080/10428194.2025.2503464
Kerem Balan, Muhammed Aslan, Emine Arzu Ayhan, Serkan Akın, Furkan Aydın, Duygu Gülseren
{"title":"Double hit lymphoma masqueraded as clusters of crater-like nonhealing infectious skin lesions.","authors":"Kerem Balan, Muhammed Aslan, Emine Arzu Ayhan, Serkan Akın, Furkan Aydın, Duygu Gülseren","doi":"10.1080/10428194.2025.2503464","DOIUrl":"https://doi.org/10.1080/10428194.2025.2503464","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-3"},"PeriodicalIF":2.2,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differences in time to treatment and impact on overall survival in adolescents and young adults with Hodgkin lymphoma. 青少年和青年霍奇金淋巴瘤患者的治疗时间差异及其对总生存率的影响。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-05-08 DOI: 10.1080/10428194.2025.2499607
Carlos A Cruz, Elizabeth R Rodriguez, Maanvi Thawani, Margaret Mazer, Matthew Hayhurst, Madison Swanson, Alexis Romero, J Andrew Livingston, Greg Aune, Debra Eshelman-Kent, Branko Cuglievan, Michael E Roth, Sairah Ahmed, Karen Albritton, Michelle A T Hildebrandt
{"title":"Differences in time to treatment and impact on overall survival in adolescents and young adults with Hodgkin lymphoma.","authors":"Carlos A Cruz, Elizabeth R Rodriguez, Maanvi Thawani, Margaret Mazer, Matthew Hayhurst, Madison Swanson, Alexis Romero, J Andrew Livingston, Greg Aune, Debra Eshelman-Kent, Branko Cuglievan, Michael E Roth, Sairah Ahmed, Karen Albritton, Michelle A T Hildebrandt","doi":"10.1080/10428194.2025.2499607","DOIUrl":"https://doi.org/10.1080/10428194.2025.2499607","url":null,"abstract":"<p><p>Delays in time to treatment (TTT) have been shown to affect cancer survival, yet this has not been investigated in adolescent and young adult (AYA) Hodgkin lymphoma (HL) patients. This retrospective analysis included 508 patients with TTT defined as the time between diagnosis and chemotherapy start. The median TTT for the population was 28 days (IQR: 12-44). Patients who reported fevers and night sweats had shorter TTT than those who did not (<i>p</i> = 0.016 and <i>p</i> = 0.017, respectively). TTT varied significantly by age group (<i>p</i> < 0.01), with adolescents (15-18 years) having nearly a 10-day shorter TTT (21.3 days) compared to a TTT of 30.2 and 31.2 days for emerging adults (19-25 years) and young adults (26-39 years), respectively. Delayed TTT was not associated with risk of death. The lack of association with survival may reflect the overall favorable survival experienced by AYA HL patients and is in line with that reported for HL across all age populations.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-7"},"PeriodicalIF":2.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144030763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma. 奈拉宾、依托泊苷和环磷酰胺治疗复发/难治性t急性淋巴细胞白血病/淋巴瘤成人的单中心研究
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-05-07 DOI: 10.1080/10428194.2025.2496333
Tamer Othman, Mimi M Lo, Charalambos B Andreadis, Lloyd E Damon, Timothy T Ferng, Karin M L Gaensler, Jerry C Lee, Thomas G Martin, Rebecca L Olin, Peter H Sayre, Catherine C Smith, Aaron C Logan
{"title":"Single-center experience with nelarabine, etoposide, and cyclophosphamide in adults with relapsed/refractory T-acute lymphoblastic leukemia/lymphoma.","authors":"Tamer Othman, Mimi M Lo, Charalambos B Andreadis, Lloyd E Damon, Timothy T Ferng, Karin M L Gaensler, Jerry C Lee, Thomas G Martin, Rebecca L Olin, Peter H Sayre, Catherine C Smith, Aaron C Logan","doi":"10.1080/10428194.2025.2496333","DOIUrl":"https://doi.org/10.1080/10428194.2025.2496333","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-4"},"PeriodicalIF":2.2,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144023372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
'A perfect match': how hematologists discuss donor options and risks with black and white patients considering allogeneic stem cell transplant. “完美匹配”：血液学家如何与考虑同种异体干细胞移植的黑人和白人患者讨论供体选择和风险。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-05-07 DOI: 10.1080/10428194.2025.2500625
Thorunn H Thordardottir, Rachel A Rodenbach, Markus Brauer, Aric C Hall, Earlise Ward, Cardinale B Smith, Toby C Campbell
{"title":"'A perfect match': how hematologists discuss donor options and risks with black and white patients considering allogeneic stem cell transplant.","authors":"Thorunn H Thordardottir, Rachel A Rodenbach, Markus Brauer, Aric C Hall, Earlise Ward, Cardinale B Smith, Toby C Campbell","doi":"10.1080/10428194.2025.2500625","DOIUrl":"https://doi.org/10.1080/10428194.2025.2500625","url":null,"abstract":"<p><p>Patients of racial minorities have lower chance of securing a suitable donor, essential part of successful allogeneic stem cell transplant. In this simulated interview study, we sought to examine how hematologists discuss donor options and risks with patients with high-risk myeloid neoplasm considering transplant. Thirty-seven US hematologists participated (65% male; 65% white, 24% Asian, none Black), randomly assigned to meet with a Black or white patient actor. The hematologists emphasized the benefits of a full match with the white patient and high chance of securing a donor. Conversely, with the Black patient, they tended not to ask about ancestry, discuss the donor registry, race implications or challenges with donor search. Knowing the patient had children, many recommended haploidentical transplant. The unique circumstances of transplant argue for a focused communication including discussing race. While conversations should be tailored to each patient, limiting essential information on donor options may contribute to disparities.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia. MYC 在慢性淋巴细胞白血病预后中的多重作用。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-02 DOI: 10.1080/10428194.2024.2447362
Loic Ysebaert, Pierre-Luc Mouchel, Camille Laurent, Anne Quillet-Mary
{"title":"The multi-faceted roles of MYC in the prognosis of chronic lymphocytic leukemia.","authors":"Loic Ysebaert, Pierre-Luc Mouchel, Camille Laurent, Anne Quillet-Mary","doi":"10.1080/10428194.2024.2447362","DOIUrl":"10.1080/10428194.2024.2447362","url":null,"abstract":"<p><p>In this review, we focus on the pro-oncogene MYC, the modes of deregulation in mouse and human B-cells, its undisputable importance in the evaluation of biological prognostication of patients, but also how it impacts on response to modern therapeutics, and how it should be targeted to improve the overall survival of chronic lymphocytic lymphoma (CLL) patients. After an overview of the current understanding of the molecular dysregulation of c-MYC, we will show how CLL, both in its indolent and transformed phases, has developed among other B-cell lymphomas a tight regulation of its expression through the chronic activation of B-Cell Receptors (among others). This is particularly important if one desires to understand the mechanisms at stake in the over-expression of c-MYC especially in the lymph nodes compartment. So doing, we will show how this oncogene orchestrates pivotal cellular functions such as metabolism, drug resistance, proliferation and histologic transformation (Richter syndrome).</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"805-817"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142915450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics. 在实验疗法时代，针对CLL关键驱动因素和测序治疗的挑战。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-19 DOI: 10.1080/10428194.2024.2445688
Britten K Gordon, Jennifer A Woyach
{"title":"The challenge of targeting key drivers of CLL and sequencing therapy in an era of experimental therapeutics.","authors":"Britten K Gordon, Jennifer A Woyach","doi":"10.1080/10428194.2024.2445688","DOIUrl":"10.1080/10428194.2024.2445688","url":null,"abstract":"<p><p>Treatment of chronic lymphocytic leukemia (CLL) has been revolutionized with the introduction of small molecule inhibitors targeting both the B-cell receptor (BCR) signaling pathway and B-cell lymphoma-2 (BCL-2) family of proteins. Inhibitors of Bruton's tyrosine kinase (BTK) and the BH3 mimetic venetoclax are bothcurrently used as the standard of care for patients in the frontline and relapsed/refractory setting of CLL. With the clinical success of both these classes of therapies, sequencing of these agents has become a major challenge in treatment of CLL. In this review we will discuss the current data available for both classes of agents in the front-line and relapsed/refractor setting, considerations when giving these agents, and how we can continue to improve the treatment landscape for CLL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"838-846"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143007674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Salvage therapy for Burkitt lymphoma with glofitamab: a case report. 格非他单抗治疗伯基特淋巴瘤1例。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-03 DOI: 10.1080/10428194.2024.2447882
Pedro Martins Almeida, Thomas Relander, Ola Linden
{"title":"Salvage therapy for Burkitt lymphoma with glofitamab: a case report.","authors":"Pedro Martins Almeida, Thomas Relander, Ola Linden","doi":"10.1080/10428194.2024.2447882","DOIUrl":"10.1080/10428194.2024.2447882","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"952-955"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142922042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glofitamab in patients with HIV-associated B-cell lymphoma. 格非他单抗在hiv相关b细胞淋巴瘤患者中的应用。
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2024-12-23 DOI: 10.1080/10428194.2024.2444470
Jose Tinajero, Tanya Markary, Dat Ngo, Swetha Kambhampati Thiruvengadam, Sabarish Ayyappan, Matthew Mei
{"title":"Glofitamab in patients with HIV-associated B-cell lymphoma.","authors":"Jose Tinajero, Tanya Markary, Dat Ngo, Swetha Kambhampati Thiruvengadam, Sabarish Ayyappan, Matthew Mei","doi":"10.1080/10428194.2024.2444470","DOIUrl":"10.1080/10428194.2024.2444470","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"969-972"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis. teclistamab治疗复发/难治性多发性骨髓瘤的安全性和有效性：来自多中心、回顾性研究和描述性荟萃分析的结果
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-05 DOI: 10.1080/10428194.2024.2446617
Gaurav Varma, Lindsay Fogel, Beth Gordon, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Maya C Rosenberg, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S Siegel, Gareth J Morgan, Ruben Niesvizky, Faith E Davies, Noa Biran
{"title":"Real-world safety and efficacy of teclistamab in relapsed/refractory multiple myeloma: results from a multicenter, retrospective study and descriptive meta-analysis.","authors":"Gaurav Varma, Lindsay Fogel, Beth Gordon, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Maya C Rosenberg, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S Siegel, Gareth J Morgan, Ruben Niesvizky, Faith E Davies, Noa Biran","doi":"10.1080/10428194.2024.2446617","DOIUrl":"10.1080/10428194.2024.2446617","url":null,"abstract":"<p><p>Patients participating in clinical trials are highly selected and may not represent the general population. The pivotal study of teclistamab (MajesTEC-1), a B-cell maturation antigen (BCMA)xCD3 bispecific antibody, demonstrated impressive response rates and progression free survival in relapsed/refractory multiple myeloma (RRMM) with acceptable toxicity. We performed a retrospective study of 58 patients treated as standard of care at four US academic centers to determine how these results translated to the real-world. Most patients (87.9%) would not have been eligible for the MajesTEC-1 study due to either disease related factors, patient related comorbidities or socio-economic/geographical factors. Despite these 'less-favorable' characteristics we observed similar efficacy and toxicity to MajesTEC-1. A meta-analysis with six other published real-world series (n = 546) confirmed these results. These data support the significant clinical activity of teclistamab in RRMM and highlights the importance of real-world data to accompany the pivotal trial data to further inform daily clinical practice.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"942-951"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142932266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma. 弥漫性大b细胞淋巴瘤老年患者的前期类固醇使用及其与剂量延迟和预后的关系
IF 2.2 4区 医学
Leukemia & Lymphoma Pub Date : 2025-05-01 Epub Date: 2025-01-08 DOI: 10.1080/10428194.2025.2450091
Alexander R Vartanov, Jill S Hasler, Elizabeth A Handorf, Zachary A K Frosch
{"title":"Prephase steroid use and association with dose delays and outcomes in a real-world cohort of older adults treated for diffuse large B-cell lymphoma.","authors":"Alexander R Vartanov, Jill S Hasler, Elizabeth A Handorf, Zachary A K Frosch","doi":"10.1080/10428194.2025.2450091","DOIUrl":"10.1080/10428194.2025.2450091","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"965-968"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142950870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信